Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21604519 | 0.83 | KDM4E (0.34) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL7914428 | 0.77 | CYP1A2 (0.41) | GAAKDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL15691375 | 0.73 | ELANE (0.33) | GAAELANE | |
| SCHEMBL16990351 | 0.73 | IDO1 (0.41) | GAAKDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL21604527 | 0.72 | HRH3 (0.46) | GAAPARP1HDAC8HRH3GRM5 | |
| SCHEMBL3684471 | 0.70 | GAA (0.51) | GAAKDM4ENPC1ALDH1A1LMNA | |
| SCHEMBL18136190 | 0.70 | SMN1; SMN2 (0.40) | KDM4EALDH1A1MAPTPKMRAB9A | |
| SCHEMBL19267574 | 0.68 | ELANE (0.39) | GAAKDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL19465805 | 0.67 | OGA (0.32) | ALDH1A1ELANE | |
| SCHEMBL19021282 | 0.66 | ALDH1A1 (0.41) | PARP1KDM4ENPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GAA 15/4885PARP1 345/4885HDAC8 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.